An herbal supplement called kratom — hailed by some as a miracle cure for heroin addiction, and assailed by others as a deadly habit-forming substance in itself — is flying off the shelves at dozens of New York city smoke shops and cafes. The Southeast Asian plant-based drug is currently in regulatory limbo, legal in...
NYS Entity Status
NYS Filing Date
NOVEMBER 19, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - CURE & CARE INC
Around the Web
- Supplement to ‘cure’ heroin addiction could be addicting too
By Melkorka Licea - Saturday Nov 11, 2017
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.
- NY's Hometown Paper Once Again Owned By Chicago Publisher
Tuesday Sep 5, 2017
New York's hometown paper is once again owned by a Chicago-based newspaper holding company, following the 'New York Daily News' sale on Monday to Tronc Inc. In a way, it's like deja vu. Tronc wasformerly Tribune Publishing, the publisher of the 'Chicago Tribune,' which originally created the 'New York Daily News' nearly a century ago.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.